Zobrazeno 1 - 10
of 262
pro vyhledávání: '"Shunichi, Sugawara"'
Autor:
Hirotsugu Kenmotsu, MD, PhD, Kazuko Sakai, PhD, Keita Mori, PhD, Terufumi Kato, MD, Shunichi Sugawara, MD, PhD, Keisuke Kirita, MD, PhD, Yasuto Yoneshima, MD, PhD, Koichi Azuma, MD, PhD, Kazumi Nishino, MD, PhD, Shunsuke Teraoka, MD, Ryo Koyama, MD, PhD, Ken Masuda, MD, PhD, Hidetoshi Hayashi, MD, PhD, Ryo Toyozawa, MD, PhD, Satoru Miura, MD, PhD, Yuki Sato, MD, PhD, Kazuhiko Nakagawa, MD, PhD, Nobuyuki Yamamoto, MD, PhD, Kazuto Nishio, MD, PhD, Toshiaki Takahashi, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 11, Pp 100716- (2024)
Introduction: EGFR tyrosine kinase inhibitors have been the standard treatment for patients with NSCLC who have sensitive EGFR mutations. This study revealed final analysis survival data, biomarkers, and resistance mechanisms of osimertinib plus beva
Externí odkaz:
https://doaj.org/article/4c7148e01a2e473a80756678fc890a30
Autor:
Soichiro Minami, Yosuke Kawashima, Yasuhiko Munakata, Masahiro Matsuno, Shuichiro Hara, Yusuke Yamazaki, Tsuyoshi Doman, Shin Saito, Tetsuo Odaka, Takahiro Ogasawara, Hisashi Shimizu, Jun Sugisaka, Tomoiki Aiba, Yukihiro Toi, Shinsuke Yamanda, Yuichiro Kimura, Shunichi Sugawara
Publikováno v:
Cancer Reports, Vol 7, Iss 7, Pp n/a-n/a (2024)
ABSTRACT Background The expansion of preoperative immunochemotherapy has led to an increase in the number of patients with lung cancer receiving immune checkpoint inhibitors (ICIs). Therefore, oncologists should manage a variety of immune‐related a
Externí odkaz:
https://doaj.org/article/5543c1d253ce41568754fb0610f4abf2
Autor:
Shunsuke Teraoka, MD, Hidetoshi Hayashi, MD, PhD, Yasushi Goto, MD, PhD, Makoto Nishio, MD, PhD, Shunichi Sugawara, MD, PhD, Takao Inoue, MD, Satoshi Oizumi, MD, PhD, Shigeyuki Toyoizumi, MS, Masakazu Matsumura, MS, Rossella Messina, PharmD, PhD, Terufumi Kato, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 3, Pp 100632- (2024)
Introduction: Lorlatinib was found to have improved efficacy versus crizotinib in the global phase 3 CROWN study (NCT03052608). Similar results were revealed for the Japanese population as for the overall population. We present results from the unpla
Externí odkaz:
https://doaj.org/article/2624fb2887e641e3b17201306189bdef
Autor:
Jun Sugisaka, Yukihiro Toi, Yosuke Kawashima, Yutaka Domeki, Tomoiki Aiba, Sachiko Kawana, Atsushi Nakamura, Shinsuke Yamanda, Yuichiro Kimura, Shunichi Sugawara
Publikováno v:
Thoracic Cancer, Vol 14, Iss 31, Pp 3140-3146 (2023)
Abstract Background There is no well‐established late‐line treatment for advanced nonsquamous non‐small cell lung cancer (NSCLC). Therefore, we retrospectively determined the efficacy and safety of platinum rechallenge with paclitaxel‐carbopl
Externí odkaz:
https://doaj.org/article/84ab70da4dee413d96eac46f9b6875a9
Autor:
Yosuke Kawashima, Osamu Ishimoto, Eisaku Miyauchi, Tomohiro Sakakibara, Toshiyuki Harada, Kazuhiro Usui, Akira Inoue, Shunichi Sugawara
Publikováno v:
Thoracic Cancer, Vol 14, Iss 27, Pp 2804-2810 (2023)
Abstract Background This phase II trial was designed to evaluate the efficacy and safety of S‐1 combined with weekly irinotecan as a second‐ or third‐line treatment for patients with advanced or recurrent squamous cell lung cancer. Methods Pati
Externí odkaz:
https://doaj.org/article/7762f015da734d1f801fd33d7a6edbc5
Autor:
Hye Ryun Kim, Shunichi Sugawara, Jong‐Seok Lee, Jin‐Hyoung Kang, Naoki Inui, Toyoaki Hida, Ki Hyeong Lee, Tatsuya Yoshida, Hiroshi Tanaka, Cheng‐Ta Yang, Makoto Nishio, Yuichiro Ohe, Tomohide Tamura, Nobuyuki Yamamoto, Chong‐Jen Yu, Hiroaki Akamatsu, Shigeru Takahashi, Kazuhiko Nakagawa
Publikováno v:
Cancer Medicine, Vol 12, Iss 16, Pp 17061-17067 (2023)
Abstract Background ONO‐4538‐52/TASUKI‐52 was performed in Japan, Korea, and Taiwan to determine the oncological effectiveness and safety of combining nivolumab or placebo with bevacizumab plus platinum chemotherapy for the initial (first‐lin
Externí odkaz:
https://doaj.org/article/b0fcd685eeec41798eee2fd83380a4ba
Autor:
Yosuke Murakami, Yosuke Kawashima, Shinji Chiba, Shuichiro Hara, Yusuke Yamazaki, Tsuyoshi Doman, Shin Saito, Tetsuo Odaka, Takahiro Ogasawara, Hisashi Shimizu, Jun Sugisaka, Tomoiki Aiba, Yukihiro Toi, Shinsuke Yamanda, Yuichiro Kimura, Shunichi Sugawara
Publikováno v:
Cancer Reports, Vol 7, Iss 2, Pp n/a-n/a (2024)
Abstract Background Anaplastic lymphoma kinase (ALK)‐positive lung cancer has a better long‐term prognosis with ALK‐inhibitor than other lung cancers. However, resistance to ALK‐inhibitors and the control of metastases in the central nervous
Externí odkaz:
https://doaj.org/article/6a69036d500340d1912700c168116d18
Autor:
Yasunori Murata, MD, PhD, Shigeru Tanzawa, MD, PhD, Toshihiro Misumi, PhD, Hiroshige Yoshioka, MD, PhD, Eisaku Miyauchi, MD, PhD, Kiichiro Ninomiya, MD, PhD, Masafumi Takeshita, MD, PhD, Kensaku Ito, MD, PhD, Tatsuro Okamoto, MD, PhD, Shunichi Sugawara, MD, PhD, Yosuke Kawashima, MD, Kazuki Hashimoto, MD, Masahide Mori, MD, PhD, Akihiko Miyanaga, MD, PhD, Anna Hayashi, MD, Hisashi Tanaka, MD, PhD, Ryoichi Honda, MD, PhD, Masafumi Nojiri, MD, PhD, Yuki Sato, MD, Akito Hata, MD, Ken Masuda, MD, PhD, Toshiyuki Kozuki, MD, PhD, Takahisa Kawamura, MD, PhD, Takuji Suzuki, MD, PhD, Teppei Yamaguchi, MD, PhD, Kazuhiro Asada, MD, PhD, Satoshi Tetsumoto, MD, PhD, Hiroshi Tanaka, MD, PhD, Satoshi Watanabe, MD, PhD, Yukihiro Umeda, MD, PhD, Kakuhiro Yamaguchi, MD, PhD, Shoichi Kuyama, MD, PhD, Kosuke Tsuruno, MD, PhD, Yuki Misumi, MD, PhD, Hiroshi Kuraishi, MD, PhD, Ken Yoshihara, MD, PhD, Akira Nakao, MD, PhD, Akihito Kubo, MD, PhD, Toshihiko Yokoyama, MD, PhD, Kana Watanabe, MD, PhD, Nobuhiko Seki, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 12, Pp 100593- (2023)
Introduction: Necitumumab plus gemcitabine and cisplatin (GCN) is a standard therapy for patients with advanced lung squamous cell carcinoma (LSqCC). However, the efficacy and tolerability of GCN in second-line or later treatment for patients previou
Externí odkaz:
https://doaj.org/article/0e1d4e104d1e4f01bd75edf40b9e925c
Autor:
Susumu Takeuchi, Kaoru Kubota, Shunichi Sugawara, Satoshi Teramukai, Rintaro Noro, Kei Fujikawa, Takashi Hirose, Shinji Atagi, Seigo Minami, Shinichiro Iida, Hiroshi Kuraishi, Tomoiki Aiba, Yuji Minegishi, Masaru Matsumoto, Masahiro Seike, Akihiko Gemma, Masaaki Kawahara, Japan‐Multinational Trial Organization (JMTO)
Publikováno v:
Cancer Medicine, Vol 12, Iss 8, Pp 9133-9143 (2023)
Abstract Background Nab‐paclitaxel (nab‐PTX) has better transfer to tumor tissue than cremophor‐based paclitaxel. It suggests that the optimum dose of nab‐PTX might be lower than the dose and schedule that is widely used. We designed a random
Externí odkaz:
https://doaj.org/article/e54f4b393bff460b86372c2ec038f9a5
Autor:
Yoshimasa Shiraishi, Junji Kishimoto, Takayuki Shimose, Yukihiro Toi, Shunichi Sugawara, Isamu Okamoto
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-5 (2022)
Abstract Background First-line treatment of nonsquamous non–small cell lung cancer (NSCLC) has undergone a paradigm shift to platinum combination therapy together with immune checkpoint inhibitors (ICIs). However, phase III studies of combinations
Externí odkaz:
https://doaj.org/article/fad4a98eec924a8eac91b100e7450863